Welcome to MOLOGEN AG

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

• U.S. investor Global Corporate Finance is providing further capital and acquiring a stake of up to 10% in MOLOGEN • Binding term sheet signed with Chinese company iPharma for the development, manufacture and commercialization of lefitolimod in the markets of China, including Hong Kong and Macao, Taiwan and Singapore • Presentation of first... [more]

Annual Report 2016
Download PDF

Quarterly Statement as at 31 March 2017
Download PDF

Half-year Report as at 30 June 2017
Download PDF

Quarterly Statement as at 30 September 2017

Download PDF